Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CAMILO JIMENEZ and JEENA VARGHESE.
CAMILO JIMENEZ
Connection Strength
3.482
JEENA VARGHESE
  1. Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice. Mol Cell Endocrinol. 2024 Oct 01; 592:112344.
    View in: PubMed
    Score: 0.978
  2. Novel germline SDHD mutation: diagnosis and implications to the patient. Fam Cancer. 2011 Jun; 10(2):365-71.
    View in: PubMed
    Score: 0.390
  3. Benign familial hypocalciuric hypercalcemia. Endocr Pract. 2011 Mar-Apr; 17 Suppl 1:13-7.
    View in: PubMed
    Score: 0.383
  4. Reply to the Letter to the Editor Concerning Metabolic and Pharma-cological Interactions of 131I-MIBG. Clin Nucl Med. 2024 Oct 10.
    View in: PubMed
    Score: 0.246
  5. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med. 2024 Jul 01; 49(7):610-620.
    View in: PubMed
    Score: 0.238
  6. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):658-667.
    View in: PubMed
    Score: 0.238
  7. TNM Staging and Overall Survival in Patients With Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. 2023 04 13; 108(5):1132-1142.
    View in: PubMed
    Score: 0.222
  8. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach. Curr Oncol Rep. 2022 01; 24(1):89-98.
    View in: PubMed
    Score: 0.204
  9. Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work? Cancers (Basel). 2022 Jan 18; 14(3).
    View in: PubMed
    Score: 0.204
  10. SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior? Ann Surg Oncol. 2024 Dec; 31(13):9007-9013.
    View in: PubMed
    Score: 0.062
  11. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist. 2024 Jul 05; 29(7):575-580.
    View in: PubMed
    Score: 0.060
  12. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol. 2024 May; 25(5):649-657.
    View in: PubMed
    Score: 0.059
  13. Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30.
    View in: PubMed
    Score: 0.058
  14. Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
    View in: PubMed
    Score: 0.052
  15. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. 2020 06; 42(6):1325-1328.
    View in: PubMed
    Score: 0.045
  16. Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study. Int J Cancer. 2020 04 01; 146(7):1836-1840.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.